CareDx Announces District Court Judge Bars Natera From Falsely Advertising And Overstating The Scientific Performance Of Its Prospera Transplant Test
Portfolio Pulse from Happy Mohamed
CareDx, Inc. (NASDAQ:CDNA) announced that the US District Court for the District of Delaware issued an injunction prohibiting Natera (NASDAQ:NTRA) from falsely advertising and overstating the scientific performance of its Prospera transplant test. This follows a decision by the District Court to uphold a March 2022 jury verdict that found Natera violated the Lanham Act by falsely advertising the test. CareDx intends to appeal the District Court's decision regarding the monetary damages awarded by the jury.
August 07, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The court's decision is a negative development for Natera, as it prohibits the company from advertising its Prospera transplant test, which could impact its sales and reputation.
The court's decision to bar Natera from advertising its Prospera transplant test could negatively impact the company's sales and reputation. This could potentially lead to decreased revenues and a drop in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
The court's decision is a positive development for CareDx, as it may help to eliminate unfair competition from Natera's falsely advertised Prospera transplant test.
The court's decision to bar Natera from falsely advertising its Prospera transplant test could reduce competition for CareDx's transplant solutions. This could potentially lead to increased market share and revenues for CareDx.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100